Previous 10 | Next 10 |
37% (7/19) patients experienced clinical benefits lasting over 6 months 12-month overall survival rate of 66.1% Translational data confirms survivin-specific CD8+ T cell immune response in 87% of subjects which supports a direct link with DPX-Survivac’...
5 Biotech Stocks To Watch This Week When it comes to biotech stocks , there’s plenty to take into account. This goes for biotech penny stocks as well. Considering that many of these companies are in the preclinical or clinical stages, there’s a higher chance that t...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company will host a key opinion leader (KOL) webcast on the treatment options in ovarian can...
IMV Inc. (IMV) Q3 2020 Earnings Conference Call November 12, 2020 08:00 ET Company Participants Pierre Labbé - CFO Frederic Ors - CEO Neil Berinstein - Hematologist & Affiliate Scientist, Sunnybrook Institute Joanne Schindler - CMO Conference Call Participants Jim Birchenough - Wells...
Gainers: EuroDry (EDRY) +64%.Innodata (INOD) +32%.Akers Biosciences (AKER) +30%.XPeng (XPEV) +29%.Cidara Therapeutics (CDTX) +27%.Fossil Group (FOSL) +26%.Li Auto (LI) +23%.Sino-Global Shipping America (SINO) +22%.Celsius Holdings (CELH) +21%.Five Prime Therapeutics (FPRX) +16%...
IMV (IMV): Q3 GAAP EPS of -C$0.13.Revenue of C$0.09M (-43.8% Y/Y)Shares -0.74% PM.Press Release For further details see: IMV reports Q3 results
Identification of PD-L1 as a potential Biomarker with 86% of clinical responses in patients with r/r DLBCL in our combination trial with Merck’s Keytruda® Cash and cash equivalents of $54.7M as of September 30 th , 2020 Expanded Board of Directors and...
Former Celgene Executive and Immunotherapy Industry Leader to Drive Development Opportunities and Path-to-Market Initiatives for IMV's Immunotherapy Pipeline IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immun...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team ...
News, Short Squeeze, Breakout and More Instantly...
GAAP Net Income of $8.3 million or $0.25 per diluted share Non-GAAP Net Income of $11.0 million or $0.33 per diluted share Declares Third Consecutive Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, to...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...